In late April 2026, the Department of Justice issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, easing federal restrictions for those categories while preserving Schedule I status for non-medical marijuana. This partial reform followed HHS's prior recommendation, but broader rescheduling awaits a DEA administrative hearing commencing June 29, 2026, and concluding by mid-July to assess scientific and medical evidence. Recent state operators' DEA registration applications and an emerging legal challenge underscore implementation hurdles. Traders monitor the hearing's outcome, potential final rulemaking timeline, and political influences amid ongoing litigation.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$758,300 交易量
2026-03-31
6月30日
3%
12月31日
25%
$758,300 交易量
6月30日
$336,927 交易量
3%
12月31日
$156,491 交易量
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, easing federal restrictions for those categories while preserving Schedule I status for non-medical marijuana. This partial reform followed HHS's prior recommendation, but broader rescheduling awaits a DEA administrative hearing commencing June 29, 2026, and concluding by mid-July to assess scientific and medical evidence. Recent state operators' DEA registration applications and an emerging legal challenge underscore implementation hurdles. Traders monitor the hearing's outcome, potential final rulemaking timeline, and political influences amid ongoing litigation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市场开放时间： Feb 7, 2026, 5:04 PM ET
交易量
$758,300结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, easing federal restrictions for those categories while preserving Schedule I status for non-medical marijuana. This partial reform followed HHS's prior recommendation, but broader rescheduling awaits a DEA administrative hearing commencing June 29, 2026, and concluding by mid-July to assess scientific and medical evidence. Recent state operators' DEA registration applications and an emerging legal challenge underscore implementation hurdles. Traders monitor the hearing's outcome, potential final rulemaking timeline, and political influences amid ongoing litigation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$758,300结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...In late April 2026, the Department of Justice issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, easing federal restrictions for those categories while preserving Schedule I status for non-medical marijuana. This partial reform followed HHS's prior recommendation, but broader rescheduling awaits a DEA administrative hearing commencing June 29, 2026, and concluding by mid-July to assess scientific and medical evidence. Recent state operators' DEA registration applications and an emerging legal challenge underscore implementation hurdles. Traders monitor the hearing's outcome, potential final rulemaking timeline, and political influences amid ongoing litigation.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题